{"preliminary_commentary":{"by_channel":{"x_thread":23,"youtube":8,"podcast":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03874884\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-31T12:04:06.365Z","note":"Automated from all 37 indexed sources (Jun 2022 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":37,"text":"- Whether olaparib adds benefit over lutetium PSMA alone\n- Whether LuPARP warrants larger randomized confirmation\n- Whether DNA-repair status should guide selection for the combination\n\nAlso discussed: DNA-damage synergy, CTC response tracking, other Lu-PSMA combinations."},"drugs_tested":[["177Lu-PSMA-617","olaparib"]],"indication":"metastatic castration-resistant prostate cancer","name":"LuPARP","nct_id":"NCT03874884","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=luparp-nct03874884. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LuPARP","arms":[{"description":"Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 6 cycles of treatment.","label":"177Lu-PSMA + olaparib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-06","type":"ESTIMATED"},"conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":{"count":70,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Olaparib","otherNames":[],"type":"DRUG"},{"name":"177Lu-PSMA","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2025-05-14","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose Limiting toxicities (DLTs)","timeFrame":"Dose escalation phase is expected to be completed 11 months from the time the first patient is recruited."},{"measure":"Maximum Tolerated dose (MTD)","timeFrame":"Dose escalation phase is expected to be completed 11 months from the time the first patient is recruited."},{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"Upto 30 months from the time the first patient is recruited."}],"references":[{"citation":"Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025 Aug 1;66(8):1265-1270. doi: 10.2967/jnumed.125.269640.","pmid":"40610228","type":"DERIVED"}],"start_date":{"date":"2019-07-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03874884"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/luparp-nct03874884"}